Integrated BioPharma Q2 revenue down 6.5% to $11.5M; net loss widens to $0.4M

INTEGRATED BIOPHARMA INC

2025-Q2 EPS reported -$0.02 revenue$24,424,000

Revenue $11.5M vs $12.3M in prior-year quarter (-6.5%).
Operating loss of ~$0.5M vs ~$33K loss a year ago.
Net loss of $0.4M ($0.01 per share) vs $3K loss ($0.00) prior year.
Six-month revenue $24.4M vs $24.6M; net loss $0.4M vs $0.1M.
Two largest customers represent ~90% of total revenue; company aims to diversify by FY2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2023 results: revenue $11.5 million, net income net loss of approximately $0.4 million, EPS $0.01.

Period: the quarter ended December 31, 2023
Revenue: $11.5 million
Net income: net loss of approximately $0.4 million
EPS: $0.01
Result: reported results

Exact text from the filing

Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ended December 31, 2022, a decrease of $0.8 million or 6.5%. The Company had operating losses for the quarters ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-24-003763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.